Stock Scorecard
Stock Summary for Akero Therapeutics Inc (AKRO) - $31.08 as of 11/20/2024 7:42:46 PM EST
Total Score
9 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for AKRO
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for AKRO
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for AKRO
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for AKRO
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for AKRO (46 out of 90)
| Stock Price Rating (Max of 10) | 8 |
| Historical Stock Price Rating (Max of 10) | 7 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 5 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 8 |
| Price to Earnings (Max of 10) | 0 |
Latest News for for AKRO
Financial Details for AKRO
Company Overview |
|
|---|---|
| Ticker | AKRO |
| Company Name | Akero Therapeutics Inc |
| Country | USA |
| Description | Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, is dedicated to developing medications designed to restore metabolic balance and improve overall health. The company is headquartered in South San Francisco, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 9/30/2024 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 31.08 |
| Price 4 Years Ago | 25.80 |
| Last Day Price Updated | 11/20/2024 7:42:46 PM EST |
| Last Day Volume | 800,232 |
| Average Daily Volume | 595,666 |
| 52-Week High | 37.00 |
| 52-Week Low | 15.32 |
| Last Price to 52 Week Low | 102.87% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.60 |
| Sector PE | 40.32 |
| 5-Year Average PE | -11.02 |
| Free Cash Flow Ratio | 2.76 |
| Industry Free Cash Flow Ratio | 12.03 |
| Sector Free Cash Flow Ratio | 27.97 |
| Current Ratio Most Recent Quarter | 17.25 |
| Total Cash Per Share | 11.28 |
| Book Value Per Share Most Recent Quarter | 10.61 |
| Price to Book Ratio | 2.80 |
| Industry Price to Book Ratio | 5.31 |
| Sector Price to Book Ratio | 20.88 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 11.82 |
| Sector Price to Sales Ratio Twelve Trailing Months | 7.11 |
| Analyst Buy Ratings | 7 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 69,799,000 |
| Market Capitalization | 2,169,352,920 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -35.46% |
| Reported EPS 12 Trailing Months | -3.78 |
| Reported EPS Past Year | -2.76 |
| Reported EPS Prior Year | -2.85 |
| Net Income Twelve Trailing Months | -237,222,000 |
| Net Income Past Year | -151,759,000 |
| Net Income Prior Year | -112,033,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00 |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 787,071,000 |
| Total Cash Past Year | 569,293,000 |
| Total Cash Prior Year | 351,449,000 |
| Net Cash Position Most Recent Quarter | 716,948,000 |
| Net Cash Position Past Year | 519,329,000 |
| Long Term Debt Past Year | 49,964,000 |
| Long Term Debt Prior Year | 19,541,000 |
| Total Debt Most Recent Quarter | 70,123,000 |
| Equity to Debt Ratio Past Year | 0.91 |
| Equity to Debt Ratio Most Recent Quarter | 0.91 |
| Total Stockholder Equity Past Year | 535,306,000 |
| Total Stockholder Equity Prior Year | 326,562,000 |
| Total Stockholder Equity Most Recent Quarter | 738,325,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -211,644,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -3.03 |
| Free Cash Flow Past Year | 0 |
| Free Cash Flow Prior Year | 0 |
Options |
|
| Put/Call Ratio | 1.17 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.47 |
| MACD Signal | 0.98 |
| 20-Day Bollinger Lower Band | 23.32 |
| 20-Day Bollinger Middle Band | 28.15 |
| 20-Day Bollinger Upper Band | 32.98 |
| Beta | -0.26 |
| RSI | 40.24 |
| 50-Day SMA | 24.79 |
| 150-Day SMA | 28.76 |
| 200-Day SMA | 28.00 |
System |
|
| Modified | 11/20/2024 5:03:36 PM EST |